Structure Therapeutics details positive trial data for a weight-loss pill, and the stock rockets
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.
Last updated: 2025-12-08 14:47:21 ET
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron, that just showed positive results from a Phase 2 trial.
Essex-based construction firm Mulalley & Co has described the continuing impact of the Grenfell tragedy as one of the factors behind its latest £3.2m...
Frank Gehry was known for designing the Guggenheim Museum Bilbao in Spain and the Walt Disney Concert Hall in Los Angeles.
'Expensive and unreliable energy'
A 25% dip in Ethereum’s voting participation coincided with a bug in the Prysm consensus client shortly after the Fusaka upgrade, with the network j...
Climate crisis and overfishing contributed to loss of 95% of penguins in two breeding colonies in South Africa, research findsMore than 60,000 penguin...
How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average person to understand.
Several factors may have affected the latest data on private-sector job losses for November. Sabrina Escobar, a reporter for Barron's, joins CBS News with more.
Following controversial large-scale immigration arrests in places like Los Angeles, Chicago and Charlotte, the Trump administration began a crackdown ...
The Los Angeles Clippers release 12-time NBA All-Star Chris Paul following the side's dreadful start to the season.